AstraZeneca Educational Webinar Series
Presented by AADE in association with AstraZeneca-US Medical Affairs, CVMD Division
This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 60 days after the live broadcast, so don't miss out!
This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.
Webinar Schedule for 2019:
All webinars will be held from 1:00-2:00 pm EST
February 13: 2019 Updates on Guidelines in the Management of T2D: Navigating CVOTs and Implications for Treatment
April 10: Cardio-Renal Complications of T2DM: Focus on Heart Failure
June 26: Diabetic Kidney Disease: New Promise for Patients Fighting a Stubborn Nemesis?
August 28: Making Sense of the CVOT Landscape in Type 2 Diabetes
October 23: The Role of the Platelet in Type 2 Diabetes Mellitus: Therapeutic Options
December 4: Managing Heart Failure Risks in People with Diabetes: New Clinical Trials with SGLT-2 Inhibitors (Register now! http://www.diabeteseducator.org/event/webi191204)
The Role of the Platelet in Type 2 Diabetes Mellitus: Therapeutic Options
Originally presented on October 23, 2019 by Narinder P. Bhalla, MD, FACC, FSCAI, and Curtis Triplitt, PharmD, CDE
The program will go over the role of the platelets in patients with Type 2 Diabetes (T2D) and the abnormal physiology of the platelets in this patient group. We will discuss how this abnormal physiology relates to the overall cardiovascular (CV) risk in patients with T2D. The data on current approved treatments will be discussed as well as some more recent data.
Upon completion of this activity, participants will be able to:
- Gain knowledge on the abnormal physiology of platelets in this patient group
- Understand the relation of abnormal platelet physiology to CV risk
- Understand the available therapeutics and newer data in this area
Managing Heart Failure Risks in People with Diabetes: New Clinical Trials with SGLT-2 Inhibitors
Wednesday, December 4, 2019 at 1:00 pm EST
Like Jiang, MD and Curtis Triplitt, PharmD, CDE will provide the evidence of increased risks of heart failure for people with type 2 diabetes and how SGLT-2i may play a role in reducing the risk.
Upon completion of this activity, participants will be able to:
- Understand the risk of heart failure in people with type 2 diabetes
- Understand the data from recent cardiovascular and heart failure studies from SGLT-2 inhibitors
- Understand guidelines and recommendations
CLICK HERE to register today!